Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/CRSP
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Crispr Therapeutics AG (CRSP) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

CRISPR Therapeutics (CRSP) trades at $57.34, up 3.45% with bullish technical signals and strong analyst support (57.9% buy ratings). The stock shows positive momentum with moving averages indicating upward trend and key resistance at $59. Despite significant revenue challenges with negative profitability metrics, the company maintains investor interest due to promising clinical developments and CASGEVY's commercial potential.
While CRSP faces substantial fundamental challenges with negative margins and cash burn, the long-term outlook remains promising due to groundbreaking gene-editing technology and upcoming clinical catalysts. Key risks include execution challenges and regulatory hurdles, but analyst consensus targets $67.83 suggest 18% upside potential from current levels.
Read full analysis

Key Stats

  • Market Cap
    $5.22B
  • Volume
    2,624,762
  • Sector
    Health
  • 52W High
    $76.78
  • 52W Low
    $44.34
  • Typical Hold Time
    77 Days
  • Enterprise Value
    $3.64B
  • Div Yield
    -
  • Trading Activity
    21% Sell | 79% Buy
$53.28
52W Low: $44.34
30 Mar 2026
52W High: $76.78
08 Oct 2025

Track Crispr Therapeutics AG (CRSP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Crispr Therapeutics AG has traded between a low of $44.34 and a high of $76.78, highlighting its annual price range. Buy and sell Crispr Therapeutics AG shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Most Recent News

Content is generated by Aura AI

MMR vaccines now available at 530+ CVS locations in New York amid measles outbreak

In response to a measles outbreak and statewide emergency in New York, CVS Health is offering measles-mumps-rubella (MMR) vaccinations at over 530 CVS Pharmacy locations and MinuteClinic sites across the state. The MMR vaccine is crucial to prevent t...

Market News
4 hours ago
PRNewsWire
Bullish
news icon
MMR vaccines now available at 530+ CVS locations in New York amid measles outbreak

Best Eli Lilly stock buys were during crises, not at hype peaks of Mounjaro and Zepbound drug approvals.

Eli Lilly's most profitable stock entry points were during less hyped events like the 2008 ImClone acquisition and the 2014 Trulicity approval, yielding returns over 2,000%. In contrast, buying at the peaks of hype around blockbuster drugs Mounjaro a...

Market News
4 hours ago
24/7 Wall Street
Neutral
Best Eli Lilly stock buys were during crises, not at hype peaks of Mounjaro and Zepbound drug approvals.

Deutsche Bank maintains 'sell' on Travis Perkins amid weak UK construction demand.

Deutsche Bank has reaffirmed its 'sell' rating on Travis Perkins with a target price of 550p, slightly below the current 572.5p share price. The bank highlights ongoing weakness in the UK construction market, noting a 10% drop in brick deliveries in ...

Market News
4 hours ago
Proactive Investors
Bearish
news icon
Deutsche Bank maintains 'sell' on Travis Perkins amid weak UK construction demand.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $5.22B
  • Volume
    2,624,762
  • Sector
    Health
  • 52W High
    $76.78
  • 52W Low
    $44.34
  • Typical Hold Time
    77 Days
  • Enterprise Value
    $3.64B
  • Div Yield
    -
  • Trading Activity
    21% Sell | 79% Buy
$53.28
52W Low: $44.34
30 Mar 2026
52W High: $76.78
08 Oct 2025

Track Crispr Therapeutics AG (CRSP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Crispr Therapeutics AG has traded between a low of $44.34 and a high of $76.78, highlighting its annual price range. Buy and sell Crispr Therapeutics AG shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!